2-Bromo-LSD_product_DataBase

Bioactivity	2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation[1].
In Vivo	2-Bromo-LSD (0.125-5.5mg/kg; 腹腔注射; 单剂量) 增加雄性斯普拉-道来氏大鼠纹状体中的体内酪氨酸羟基化，还增加 DOPA 的积累，最小作用剂量为 0.125 mg/kg[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
CAS	478-84-2
Formula	C20H24BrN3O
Molar Mass	402.33
Appearance	固体
Transport	Room temperature in continental US; may vary elsewhere.
Storage	-20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Reference	[1]. Persson SA. The effect of LSD and 2-bromo LSD on the striatal DOPA accumulation after decarboxylase inhibition in rats. Eur J Pharmacol. 1977 May 1;43(1):73-83.

PeptideDB